Cochrane Abstracts
Oral versus intravenous fluoropyrimidines for colorectal cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral Versus Intravenous Fluoropyrimidines for Colorectal Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434871/all/Oral_versus_intravenous_fluoropyrimidines_for_colorectal_cancer.
Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434871/all/Oral_versus_intravenous_fluoropyrimidines_for_colorectal_cancer. Accessed May 16, 2025.
Oral versus intravenous fluoropyrimidines for colorectal cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434871/all/Oral_versus_intravenous_fluoropyrimidines_for_colorectal_cancer
Oral Versus Intravenous Fluoropyrimidines for Colorectal Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 May 16]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434871/all/Oral_versus_intravenous_fluoropyrimidines_for_colorectal_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral versus intravenous fluoropyrimidines for colorectal cancer
ID - 434871
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434871/all/Oral_versus_intravenous_fluoropyrimidines_for_colorectal_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
